Celularity Inc
CELU
Company Profile
Business description
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.
Contact
170 Park Avenue
Florham ParkNJ07932
USAT: +1 908 768-2170
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
120
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,369.30 | 4.70 | -0.06% |
| CAC 40 | 7,696.92 | 31.01 | -0.40% |
| DAX 40 | 23,249.65 | 94.89 | -0.41% |
| Dow JONES (US) | 40,829.00 | 389.83 | -0.95% |
| FTSE 100 | 8,597.42 | 1.07 | 0.01% |
| HKSE | 22,662.71 | 158.03 | 0.70% |
| NASDAQ | 17,689.66 | 154.58 | -0.87% |
| Nikkei 225 | 36,830.69 | 378.39 | 1.04% |
| NZX 50 Index | 12,461.78 | 40.69 | 0.33% |
| S&P 500 | 5,606.91 | 43.47 | -0.77% |
| S&P/ASX 200 | 8,151.40 | 6.40 | -0.08% |
| SSE Composite Index | 3,316.11 | 37.08 | 1.13% |